Search

everythinglearnresearchcommunity

for

Search:↓

COVID-19 may cause hair loss, often after recovery, with androgenetic alopecia being the most common type.

Hirsutism is excessive hair growth in women often caused by polycystic ovarian syndrome, and identifying the cause is important for managing associated health risks.

The document concludes that accurate diagnosis and personalized treatment are important for skin problems in women with PCOS.

The document concludes that managing non-classical congenital adrenal hyperplasia in females requires personalized treatment, genetic counseling, and a team of specialists.

Effective PCOS treatments require targeting specific signaling pathways.

The conclusion is that the best initial treatment for hirsutism is usually oral contraceptives, with the addition of antiandrogens or insulin sensitizers if needed, and topical eflornithine or laser treatments as supplementary options.

Doctors should know how to diagnose and treat PCOS, which often involves checking for high male hormone levels and using medications to manage symptoms.

Antiandrogens can treat female hormonal conditions, but environmental ones may harm reproductive health.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

There is no significant link between insulin resistance and certain hair disorders like idiopathic hirsutism and androgenic alopecia.

Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.

Hair loss is a common side effect of hormone treatments for cancer.

Treating hirsutism in women often requires a mix of medications and cosmetic methods for best results.

Environmental factors like diet and vitamin levels, especially Vitamin D, can affect autoimmune diseases differently, with lifestyle changes potentially improving outcomes.

Most women with excess male hormones have Polycystic Ovary Syndrome, and hormonal therapy can improve symptoms but may cause side effects.

Polycystic Ovary Syndrome is linked to higher risk of hypertension and heart disease.

The document concludes that managing PCOS involves treating symptoms and reducing long-term metabolic risks, with lifestyle changes being important.

The research found that PCOS has common genetic factors regardless of how it is diagnosed and is linked to metabolic and reproductive issues.

Women with PCOS face higher risks of diabetes and heart disease, and these risks increase with obesity.

Dienogest combined with ethinylestradiol is a highly effective birth control that improves menstrual symptoms and has manageable side effects.

Antiandrogens, particularly flutamide and CPA, are most effective for treating hirsutism, with long-term use needed for best results.

AMH helps estimate ovarian reserve but doesn't predict pregnancy chances; age is more important.

Women with PCOS are more likely to have insulin resistance and obesity, especially those with the most severe type I PCOS.

The review found no clear link between vitamin D receptor gene variations and polycystic ovary syndrome.

Women with PCOS have a higher risk of diabetes, heart problems, certain cancers, and mental health issues, but early treatment can help manage these risks.

Losing 5-10% body weight can improve PCOS symptoms, letrozole is better than clomiphene for fertility, and managing weight and blood sugar is important to reduce pregnancy complications.

The document concludes that hormonal biomarkers are key for diagnosing hyperandrogenemia in women and hypogonadism in men.

Combination therapy with oral contraceptives and spironolactone improves hair growth, menstrual issues, and acne in women with PCOS.

PSA levels could help detect illegal steroid use in female athletes but face challenges like cost and PCOS prevalence.

AMH levels are higher in women with PCOS and can indicate the number of small follicles in their ovaries.